Literature DB >> 9434723

Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.

L A Morrison1, D M Knipe.   

Abstract

Replication-defective mutants of herpes simplex virus 1 (HSV-1) elicit immune responses in mice that reduce acute and latent infection after corneal challenge and are protective against development of disease. To understand the basis for the protective immunity induced by this new form of immunization, we investigated the contribution of various components of the immune response to protection against corneal infection and disease. Passive transfer of sera from mice immunized with the replication-defective mutant virus, d301, its parental HSV-1 strain, or uninfected cell lysate was used to examine the role of antibody. Despite posttransfer neutralizing antibody titers equivalent to those in control mice directly immunized with mutant virus, recipients of immune serum showed no reductions in primary replication in the eye, keratitis, or latent infection of the nervous system. However, immune serum protected mice from encephalitis and death. To examine the contribution of T cell subsets to protection, mice were immunized once with mutant virus and then were depleted in vivo of CD4+ or CD8+ T cells prior to corneal challenge. CD4 depletion resulted in higher titers of challenge virus in the eye at 3 to 4 days after challenge compared to control mice. Latent infection of the nervous system was increased by depletion of CD4+ T cells but not by depletion of CD8+ T cells keratitis developed only in a portion of the CD8+ T cell-depleted mice, suggesting that an immunopathologic potential of CD4+ T cells is held in check when immune CD8+ T cells are also present. Taken together, these data support a role for antibody induced by immunization with a replication-defective virus principally in protecting the central nervous system from disease, roles for CD4+ T cells in reducing primary replication in the eye and protecting against latent infection of the nervous system, and a role for CD8+ T cells in regulating the immunopathologic activity of CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9434723     DOI: 10.1006/viro.1997.8884

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Activation of NF-κB in CD8+ dendritic cells Ex Vivo by the γ134.5 null mutant correlates with immunity against herpes simplex virus 1.

Authors:  Huali Jin; Yijie Ma; Zhipeng Yan; Bellur S Prabhakar; Bin He
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Effective vaccination against long-term gammaherpesvirus latency.

Authors:  Scott A Tibbetts; J Scott McClellan; Shivaprakash Gangappa; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency.

Authors:  James Scott McClellan; Scott A Tibbetts; Shivaprakash Gangappa; Kelly A Brett; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1.

Authors:  Felix N Toka; Malgorzata Gierynska; Barry T Rouse
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 6.  Immune regulation of viral infection and vice versa.

Authors:  Herbert W Virgin
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.

Authors:  David J Davido; Eleain M Tu; Hong Wang; Maria Korom; Andreu Gazquez Casals; P Jahnu Reddy; Heba H Mostafa; Benjamin Combs; Steve D Haenchen; Lynda A Morrison
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

8.  Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.

Authors:  Tammie L Keadle; Lynda A Morrison; Jessica L Morris; Jay S Pepose; Patrick M Stuart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells.

Authors:  Mark A Brockman; Admar Verschoor; Jia Zhu; Michael C Carroll; David M Knipe
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

10.  The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.

Authors:  Hanka Augustinova; Daniela Hoeller; Feng Yao
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.